The biodistributions of [111In]In-DTPA-anti-PD-L1-BC and [225Ac]Ac-DOTA-anti-PD-L1-BC (an anti-PD-L1 antibody, expressed on various cancers) have been compared in tumor-bearing mice and pharmacokinetic differences in certain tissues were found, with 111In having higher %ID/g in the kidneys and tumor, and 225Ac having twice as high %ID/g in the liver at the 24 hour timepoint. This evidence concerns the gene CD274 and cancer.